Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Beta-D-Glucose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.56 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | PYGB | P11216 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| B-D-Galactose SCHEMBL27583177 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| B-D-Galactose SCHEMBL364282 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| Dextrose SCHEMBL3364163 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| Dextrose SCHEMBL30949013 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| B-D-Galactose SCHEMBL8154323 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| D-Galactose SCHEMBL4243715 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| D-Allose SCHEMBL29540485 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| Dextrose SCHEMBL30912332 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| B-D-Galactose SCHEMBL3939815 | 1.00 | LGALS3 (0.56) | LGALS3LGALS1LGALS9LGALS8MAPT | |
| Dextrose SCHEMBL28198766 | 0.97 | LGALS3 (0.54) | LGALS3LGALS1LGALS9LGALS8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010068601-A1 | A CRYSTALLINE HETEROAROMATIC FLUOROGLYCOSIDE HYDRATE, PROCESSES FOR MAKING, METHODS OF USE AND PHARMACEUTICAL COMPOSITIONS THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | WO | claimed |
| CN-1383381-A | Therpauetic agent of osteoporisis comprising active ingredient of quercetin derivatives | KOREA INST ORIENTAL MEDICINE (KR) | 2002-12-04 | — | — | CN | claimed |
| US-12011452-B2 | Compositions and methods for treatment of mitochondrial respiratory chain dysfunction and other mitochondrial disorders | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240180938-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-06-06 | — | — | US | disclosed |
| CN-115015450-B | Method for analyzing metabolites in soil by microwave derivatization-quasi-target gas chromatography-mass spectrometry | 贵州省烟草科学研究院 | 2024-05-14 | — | — | CN | disclosed |
| CN-115015450-A | Method for analyzing metabolites in soil through microwave derivatization-quasi-target gas chromatography-mass spectrometry | 贵州省烟草科学研究院 | 2022-09-06 | — | — | CN | disclosed |
| EP-3813837-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS | The Children's Hospital Of Philadelphia (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10906981-B2 | Compositions and methods related to structures that cross the blood brain barrier | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-02 | — | — | US | disclosed |
| CN-111018928-A | Synthetic method and application of gastrodin hemihydrate | 北京悦康科创医药科技股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2020006321-A9 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2020-04-02 | — | — | WO | disclosed |
| CN-110831633-A | Peptide linker and cryptophycin conjugate for therapy and preparation thereof | 赛诺菲 | 2020-02-21 | — | — | CN | disclosed |
| CN-104245718-B | Prepare fondaparinux sodium method and synthesis in use intermediate | 可靠生物医药公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-106029628-A | Multifunctional (meth)acrylate manufacturing method | 东亚合成株式会社 | 2016-10-12 | — | — | CN | disclosed |
| US-20160152719-A1 | COMPOSITIONS AND METHODS RELATED TO STRUCTURES THAT CROSS THE BLOOD BRAIN BARRIER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| WO-2015009961-A1 | COMPOSITIONS AND METHODS RELATED TO STRUCTURES THAT CROSS THE BLOOD BRAIN BARRIER | ARMAGEN TECHNOLOGIES, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| CN-102574931-B | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof | SANOFI AVENTIS | 2014-07-02 | — | — | CN | disclosed |
| CN-102574931-A | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof | SANOFI AVENTIS | 2012-07-11 | — | — | CN | disclosed |
| CN-1383381-A | Therpauetic agent of osteoporisis comprising active ingredient of quercetin derivatives | KOREA INST ORIENTAL MEDICINE (KR) | 2002-12-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180938-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS | NDUFAB1, NDUFB3, NDUFB7 | LGALS3 3538/4885LGALS1 3955/4885LGALS9 4263/4885 |
| US-12011452-B2 | Compositions and methods for treatment of mitochondrial respiratory chain dysfunction and other mitochondrial disorders | NDUFAB1, NDUFB3, NDUFB7 | LGALS3 3538/4885LGALS1 3955/4885LGALS9 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.